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The proteasome is the machinery in eukaryotic cells that degrades protein and 
recycles the amino acids.  Protein degradation is a highly regulated process which starts 
by the attachment of chains of ubiquitin, which serves as a tag that marks a protein for 
degradation. This function involves the work of several proteins at the proteasome that 
work either as ubiquitin chaperones, ubiquitin binders or cleave ubiquitin from the 
protein that is to be degraded. As this is a highly regulated process, various irregularities 
can have deleterious effects including the onset of disease, including cardiovascular, 
cancer, and neurological. 
The focus of this dissertation is to study how residues located within and outside 
the active site of Ubiquitin Carboxyl Terminal Hydrolase (UCH) deubiquinating enzymes 
(DUBS) help regulate these enzymes interaction with the ubiquitin. I will provide 
evidence that the putative oxyanion glutamine does function contribute to stabilization of 
the oxyanion intermediate. Secondly, I will show that evidence that glutamine may also 
serve another function within the active site by providing a CHO hydrogen bond that was 
previously thought not to exist within the active sites of cysteine proteases. Lastly, I will 












1.1 Ubiquitin-Proteasome System 
 
The proteasome is the machinery in eukaryotic cells that degrades protein and 
recycles the amino acids.  Protein degradation is a highly regulated process.  Ubiquitin is 
attached to proteins marked for degradation. Ubiquitin however is not degraded by the 
proteasome. Instead, the ubiquitin chain is cleaved by an enzyme at the proteasome cap 
called deubiquitinating enzymes or DUBS.  Proteins are tightly regulated in the cell by 
the ubiquitin proteasome system. Ubiquitination is the covalent attachment of the 76 
amino acid containing eukaryotic polypeptide ubiquitin and is an important reversible 
post-translational modification of proteins in the cell. It helps regulates a wide variety of 
biological process, such as cell cycle control, transcription, and protein quality control [3-
5].  Ubiquitin is attached through an isopeptide bond between the C-terminal carboxy-
terminal group of ubiquitin and the Ɛ-amino group of a lysine side chain[1].  This 
reaction is catalyzed by the sequential action of three enzymatic systems termed E1, E2, 
and E3 [4].  Ubiquitin is first activated by E1 in an ATP-dependent reaction that results in 
its installation on the E1 enzyme through a thioester bond between the c-terminal 
carboxylic acid of ubiquitin and the catalytic cysteine of E1.  The activated ubiquitin is 
then transferred to the E2 enzymes catalytic cysteine residue.  The E3 enzyme serves the 
function of a protein ligase.  E3 links ubiquitin to the acceptor protein’s lysine residue.  
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Once this isopeptide bond is formed, more ubiquitins are linked to form a polyubiquitin 
chain. There are estimated to be more than 600 E3 proteins found in the human genome 
[5]. E3 are responsible for the type of polyubiquitin chain tagged to the proteins.  The 
type polyubiquitin linkages are identified by the lysine on ubiquitin and the carboxy 
terminus of the next ubiquitin where the bond is formed. The linkages that have been 
identified are K6, K11, K27, K29, K33, K48, and K63. Of these only the roles of K11, 
K48, and K63 have been determined[6-10]. K11 and K48 both have been found to be the 
primary linkage to confer proteasome degradation. While K63 linked substrates are 
responsible for non-degradative functions such as cellular signaling, intracellular 
trafficking, and ribosomal biogenesis [8-12].  The process is ultimately regulated by 
deubiquinating enzymes (DUBs), which catalytic activities oppose that of the E3 
enzymes by editing the polyubiquitin chain or cleaving the ubiquitin directly from the 
substrate, creating more fee ubiquitin [12].  There are five classes of over 90 DUBs in the 
human genome: the cysteine protease comprising the  ubiquitin c-terminal hydrolases 
(UCHs) family, the ubiquitin specific proteases (USPs) family, the ovarian tumor 
proteases (OTU) family, the Machado-Josephin Domain protease (MJDs) family and the 
last family, the  JAB1/MPN/MOV34 (JAMM) protease family, are metalloproteases [13-
15].  
 
1.2 Ubiquitin C-Terminal Hydrolases 
Of the five DUB families, the ubiquitin c-terminal hydrolase family is unique 
because there active sites contain a cross-over loop that restricts the substrate access  .  
There are four members of the UCH family; UCHL1, UCHL3, UCHL5 (UCH37), and 
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BAP1 .  It is the first DUB family to be identified however the substrate preference for 
each enzyme has not yet been determined [18]. Each family member is composed of a 
UCH domain with UCH37 and BAP1 having extensions at their c-terminus [1-3]. 
Ubiquitination is the covalent attachment of the 76 amino acid containing eukaryotic 
polypeptide ubiquitin and is an important reversible post-translational modification of 
proteins in the cell. It helps regulates a wide variety of biological process, such as cell 
cycle control, transcription, and protein quality control [3-5]. Ubiquitin is attached 
through an isopeptide bond between the C-terminal carboxy-terminal group of ubiquitin 
and the Ɛ-amino group of a lysine side chain[1].  This reaction is catalyzed by the 
sequential action of three enzymatic systems termed E1, E2, and E3 [13, 19].  Ubiquitin 
is first activated by E1 in an ATP-dependent reaction that results in its installation on the 
E1 enzyme through a thioester bond between the c-terminal carboxylic acid of ubiquitin 
and the catalytic cysteine of E1.  The activated ubiquitin is then transferred to the E2 
enzymes catalytic cysteine residue.  The E3 enzyme serves the function of a protein 
ligase.  E3 links ubiquitin to the acceptor protein’s lysine residue.  Once this isopeptide 
bond is formed, more ubiquitins are linked to form a polyubiquitin chain.  The process is 





UCHL3 was one of the first structurally characterized in the UCH family and 
also the smallest at just 8.6 kDa [15, 21]. The primary responsibility of UCHL3 has yet to 
be determined. It is understood from structure that it has a crossover loop presumably for 
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conferring substrate specificity [13, 20]. The loop is found to be disordered in the human 
enzyme but takes an ordered conformation when bound to ubiquitin [15, 22]. UCHL3 
shows hydrolase activity to linearly fused ubiquitin to small peptides [22]. It has been 
found to be upregulated in uterine cervical neoplasms and to be a novel regulator in 




UCHL1 is a (223 amino acid), 24 kDa protein that belongs the UCH family of 
DUBs.  It is selectively expressed in the brain comprising 1-2% of all brain protein.  
Mutations in UCHL1 have been linked to neurodegenerative diseases. UCHL1 has been 
identified in lewy bodies in Parkinson’s disease [25]. UCHL1 is not expressed in normal 
lung tissue. This gives UCHL1 implications in lung cancer tumor regulation and 
metastasis[10].  UCHL1 monomer is composed of two lobes, a right and left.  The right 
lobe of L1 consisting of five αα helixes [10].  The left lobe of L1 consists of two αα 
helices and six β strands.  Between the lobes is a cleft that contains the catalytic residues.  
The active site is composed of three secondary structural elements; αa helix, a ββ sheet, 
and a loop.  The helix contains the catalytic cysteine (Cys90). The β sheet contains the 
catalytic histidine (His 161).  The loop contains the catalytic aspartic acid (Asp 176) [26].  
These three residues make up UCHL1 catalytic triad and are responsible for UCHL1’s 










UCHL5 (UCH37)  is a 329 amino acid DUB of the UCH family. Its specific 
function is for ubiquitin chain editing, presumably at the distal end, at the 19S 
proteasome [27].  It has been found to dock to the 19S regulatory particle through the 
interactions with the subunit Rpn13.  UCHL5 and RPN13 share a similar construct in 
their c-terminal region called a KEKE motif. The KEKE motif is a series of repetitive 
lysine and glutamate residues.  This motif is believed to be responsible for this 
interaction.  UCHL5’s activity toward poly-ubiquitin chains is mediated by its association 
with RPN13, which provides an additional ubiquitin binding site for the poly-ubiquitin 




BRCA1 associated protein 1 (BAP1) is the largest member of the UCH family. In 
addition to the N-terminal UCH domain, it contains several interacting domains along 
with a nuclear localization site (NLS) [28]. BAP1 interactes with the RING finger 
domain of BRCA1 [29]. Sequence analysis identified the amino-terminal segment of 
BAP1 as a ubiquitin hydrolase, which was confirmed through activity measurements 
against a     Ub-OEt substrate mimic[30]. BAP1 is the last member of the UCH family 
that has not had its structure determined.  Further characterization of the enzyme revealed 
that BAP1 contained two nuclear localization sites and that BAP1 co-immunprecipitated 
with a splicing variant of BRCA1. This led to the understanding that the ubiquitin 
degradation pathway could play a role in the regulation of BRCA1. Because the sequence 
of BAP1 that interacts with BARD1 overlaps with the UCH domain (residues 182-365), 
6 
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CHAPTER 2: CONTRIBUTION OF PUTATIVE OXYANION HOLE RESIDUE TO 
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Ubiquitin carboxy terminal hydrolases (UCHs) catalyze the hydrolytic removal of 
ubiquitin from ubiquitinated proteins. These deubiquinating enzymes are cysteine 
proteases featuring a classical cysteine-histidine-aspartate catalytic triad, also a highly 
conserved glutamine thought to be a part of the oxyanion hole. However, the contribution 
of this side chain to the catalysis by UCH enzymes is not known.  
 In this study, we demonstrate through mutational analysis that the putative 
oxyanion-stabilizing side chain contributes to rate enhancement in UCHL1, UCHL3 and 
UCHL5. Mutation of the glutamine to alanine in these enzymes reduces the catalytic 
efficiency, mainly due to a 16 to 30-fold reduction in kcat (2 kcal/mol).  
 
2.2  Introduction 
Ubiquitin carboxy-terminal hydrolases (UCHs) belong to a larger group of 
enzymes collectively called deubiquitinases (DUBs), which catalyze the hydrolysis of the 
peptide or isopeptide bond through which ubiquitin is attached to other proteins or other 
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ubiquitin moieties in polyubiquitin chains [12, 35, 36]. The UCH family members are 
cysteine proteases featuring a classical cysteine-histidine-aspartate catalytic triad [12, 15, 
16, 22]. The active site of these enzymes also features a highly conserved glutamine 
residue (Fig. 2.1) believed to be a part of the so-called oxyanion hole, an arrangement of 
spatially proximal peptide dipoles aligned in a way that creates a positively charged 
pocket facing the thiol group of the catalytic cysteine. It is also possible that, by virtue of 
being located at the N-terminus of a helix, the electropositive character of this pocket is 
enhanced by the helix macro dipole effect [6]. In cysteine proteases, nucleophilic attack 
of the carbonyl group on the scissile peptide bond proceeds through a tetrahedral 
transition state bearing a   negative charge on the oxygen atom of the carbonyl group. 
This negative charge is stabilized by electrostatic and hydrogen-bonding interactions with 
the oxyanion hole, which is proposed to be one of the factors leading to the lowering of 
activation energy for the hydrolysis reaction [6].  
  The relative orientation of the carbonyl oxygen of the scissile peptide group with 
respect to the oxyanion-stabilizing groups, as in the tetrahedral transition state, may be 
approximately visualized in the crystal structure of the yeast ubiquitin hydrolase Yuh1 
bound covalently to the suicide substrate ubiquitin aldehyde (Ubal) (Fig. 2) [6]. Attack of 
the catalytic thiol on Ubal results in the formation of the thiohemiacteal product, which 
mimics the oxyanion-bearing tetrahedral transition state (Fig. 2). As seen in Figure 2, the 
hydroxyl oxygen of the thiohemiacetal moiety is within a relatively short distance from 
the backbone NH groups of the catalytic Cys90, Ala89, Asn88 and the side chain NH2 
group of Gln84, the putative oxyanion-stabilizing side chain. It has been proposed that in 
a general cysteine protease, the negatively charged oxygen in the tetrahedral transition 
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state would occupy nearly the same position as the thiohemiacteal hydroxyl oxygen seen 
in the Yuh1-Ubal structure and would be coordinated through electrostatic and hydrogen-
bonding interactions by the groups lining the oxyanion hole [7]. 
   Papain, an extensively studied cysteine protease, revealed that Gln19, the 
oxyanion side chain in the protein, plays a role in the catalytic mechanism of the enzyme 
contributing to rate enhancement [7]. Mutation of this side chain to alanine reduces the 
catalytic efficiency approximately 60-fold, mostly affecting kcat (20-fold lower) with a 
relatively smaller change in KM (3-fold higher) [8]. Ignoring the relatively small change 
in KM, the 20-fold change in kcat was attributed to a loss of the contribution of the 
glutamine side chain to oxyanion stabilization. The catalytic Cys-His-Asp triad of 
structurally characterized UCH enzymes, such as UCHL1, UCHL3 and UCHL5, adopts a 
similar geometric relationship as found in the Cys-His-Asn triad of papain and the triads 
of other papain-like cysteine proteases. Additionally, the active-site glutamine in UCH 
enzymes is located in an identical location as the as Gln19 in papain. However, the role 
played by this side chain in the catalysis by UCH enzymes has not been studied thus far. 
Considering the importance of the UCH group of proteases in diseases such as 
Parkinson’s disease and cancer, understanding the role of active site residues in catalysis 
is important for our overall understanding of the mechanism of these enzymes[9]. We 
sought to determine the contribution to rate enhancement by the putative oxyanion 






2.3  Materials and Methods 
Ubiquitin 7-amido-4-methylcoumarin (Ub-AMC) used for hydrolysis assays was 
acquired from Boston Biochem (Boston, MA). The glutathione affinity column (GSTPrep 
FF 16/10), gel filtration column (HiLoad 16/60 Superdex 75) and PreScission protease 
were purchased from GE Biosciences (USA). All fluorescence assays were performed on 
a TECAN Genios microplate spectrofluorometer. Buffer and salt components were 
purchased from either Sigma-Aldrich (St. Louis, MO) or RPI Corp (Mount Prospect, IL).  
 
2.3.1 Mutagenesis, Protein Expression and Purification 
UCHL1, UHCL3, UCHL5N240 were cloned into the pGEX-6P-1 vector using 
standard protocols and subsequently used to mutate the active-site glutamine to alanine 
through PCR reactions using the Quickchange II (Agilent; Santa Clara, CA) site-directed 
mutagenesis kit. All plasmids were transformed into Rosetta2 E. coli cells and grown to 
an ODλ600nm= 0.6 in LB media supplemented with 100 μg/mL ampicillin then induced 
with 0.5 mM isopropyl β-thiogalactoside and grown overnight at 18°C. Cells were 
harvested at 6,000 × g and resuspended in 1X PBS + 400 mM KCl (buffer A). Cells were 
passed through a French press twice at 1,200 psi and the lysate cleared by centrifugation 
at 30,000 × g for 1 hour. The supernatant was loaded onto a glutathione affinity column, 
washed with 3 column volumes of buffer A and eluted with 250 mM Tris, 500 mM KCl, 
10 mM reduced L-glutathione, pH 8.0. The eluted sample was dialyzed against 1X PBS, 
400 mM KCl, 1 mM DTT to which PrecissionProtease was added to remove the 
glutathione S-transferase (GST) tag, which was captured onto a glutathione-agarose 
affinity column. The resulting GST-cleaved protein solution was passed through a 
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Superdex S75 gel filtration column with 50 mM TRIS-HCl (pH 7.6), 150 mM NaCl and 
1mM DTT. Fractions containing purified protein were pooled, concentrated then flash 
frozen in liquid nitrogen and stored at -80 °C until use.  
 
2.3.2 Analysis of Oxyanion Mutants 
Each of the UCH enzymes was diluted in assay reaction buffer (50 mM Tris pH 
7.6, 0.5 mM EDTA, 0.1% BSA, 5 mM DTT) so the final concentration in the reaction is 
the following: UCHL1 (2 nM), UCHL1 Q84A (8 nM), UCHL3 (5 pM), UCHL3 Q89A 
(175 pM), UCHL5N240 (500 pM), UCHL5N240 Q82A (3 nM), UCHL3 Q89E (12 pM), 
UCHL3 Q89K (50 pM). Enzyme was added to a 96-well plate and incubated at 30°C for 
5 min prior to addition of Ub-AMC diluted in assay reaction buffer to initiate the 
reaction. Rates of Ub-AMC cleavage was monitored with an excitation λ = 380 nm and 
an emission λ = 465 nm at 30°C. Initial reaction rates were calculated and plotted versus 
Ub-AMC concentration in SigmaPlot and fitted to the Michaelis-Menten equation to 
determine KM and kcat values. 
 
2.4  Results 
 
2.4.1 Alanine Mutants Show Modest Loss of Activity 
In order to determine if the conserved glutamine residue found in the active site of 
UCH enzymes (fig. 2.3) contributes to rate enhancement, hydrolysis assays using the 
fluorogenic substrate Ub-AMC were conducted using identical conditions for each set of 
enzyme and its glutamine to alanine mutant. These results show that the rate of 
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hydrolysis leading to AMC release is significantly reduced in the mutants compared to 
their wild-type enzymes seen in figure 2.3, suggest that this side chain plays some role in 
the catalytic mechanism of the enzymes. Since glutamine is located in the solvent-
accessible active site of the enzymes, the mutation of this residue to alanine is not 
expected to cause any significant perturbation in the active-site structure or gross changes 
in the three-dimensional fold of the protein. In fact, the circular dichroism spectra of the 
mutants produce a pattern that is nearly identical in shape and intensities to their 
corresponding wild-type proteins confirming that the mutation has no observable 
structural effect in these proteins [10-12].  
The loss in catalytic activity observed upon mutation could be attributed to two 
possible factors: an increase in the Michaelis constant KM, or a reduction in kcat, the rate 
constant of the rate determining step in the hydrolysis reaction. In order to know which 
parameters are affected by the mutation, we set out to analyze the Michaelis-Menten 
kinetics of the mutants and the wild-type enzymes. Additional activity assays were 
conducted with varying substrate concentration and plots of the initial velocities versus 
substrate concentration are shown in figure 2.4 All enzymes with the exception of 
UCHL5N240 Q82A were fit to the Michaelis-Menten equation (figure 2.4). Non-linear 
regression analysis of the plots yielded the kinetic parameters kcat and KM for each UCH 
variant and their values are provided in Table 2.1. The values of the kinetic parameters 
obtained with wild-type enzymes are consistent with previously reported values  . The 
glutamine to alanine mutants showed a 30 and 18-fold decrease in kcat, for UCHL1 and 
UCHL3, respectively, compared to their corresponding wild-type enzymes. However, KM 
values were relatively unchanged due to the mutation, which is consistent with the 
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hypothesis that the glutamine residue is involved in the catalytic mechanism of the 
enzyme.  
In the case of UCHL5N240 Q82A, kcat and KM could not be determined 
individually because, even at concentrations of Ub-AMC as high as 12 M, the 
Michaelis-Menten plot was still rising linearly with substrate concentration, not reaching 
the plateau that is diagnostic of saturation.  Substrate concentrations greater than 12 M 
result in DMSO concentrations higher than 5%, which can diminish the enzyme’s 
activity. Instead, the ratio kcat/KM was determined by dividing the slope of this linear plot 
by the total enzyme concentration since it can be assumed that in this region of the 
Michaelis-Menten plot,  [Ub-AMC] << KM. Comparison of this value for the wild-type 
and Q82A variant of UCHL5N240 shows a 16-fold reduction in catalytic efficiency, 
which is comparable to the reductions seen with UCHL1 and UCHL3 suggesting that the 
Gln82 residue is likely performing the same function as in the other UCH enzymes.   
In order to determine the effect of these mutations on the stabilization of the transition 
state, we sought to estimate the change in free energy of activation associated with the 
mutation. The calculation was carried out using equation 2.1 and the kcat/KM values 
mentioned above and reported in Table 2.1 [11]. The free energy change for the three 
enzymes is approximately 2 kcal/mol, which is consistent with the value reported for the 












)/K(kln-RT=G Equation 2.1 
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The active-site glutamine in UCH enzymes is involved in a C—H•••O hydrogen 
bond with CH of the catalytic histidine 
 
2.5 Discussion 
The UCH subfamily of dubiquitinases are cysteine proteases with a catalytic triad 
similar to that seen in the papain family. In each member of this family, like papain, there 
is a conserved glutamine residue located in the active site of the enzymes believed to 
stabilize the incipient negative charge on the carbonyl of the scissile bond during the 
transition state of the hydrolysis reaction (Scheme 2.1). Indeed, mutation of the Gln19 in 
papain to alanine resulted in a 60-fold decrease in catalytic efficiency due mainly to a 
diminished catalytic rate (20-fold) and a small loss in substrate binding (3-fold). These 
results support the claim that the conserved glutamine side chain contributes to the 
stabilization of the oxyanion transition state. Given the similarity in certain active-site 
residues between papain and members of the UCH family, we wondered if the glutamine 
would perform a similar role in the UCH family. Our study sought to address the role of 
the conserved glutamine in rate enhancement in three UCH enzymes. 
Through site-directed mutagenesis, the active-site glutamine in three structurally 
characterized members of the UCH family was replaced with alanine in order to assess 
the contribution of this side chain to rate enhancement. Deubiquitination assays show 
there is a significant loss of activity in mutant enzymes compared to their wild-type 
counterparts. Comparison of the kinetic parameters shows a 16 to 30-fold loss (~2 
kcal/mol) in the catalytic efficiency for the glutamine mutants, which is due mainly to a 
decrease in the kcat parameter, as seen in UCHL1 and UCHL3 (for the mutant UCHL5, 
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kcat and KM could not be separately determined). These results are in agreement with the 
aforementioned results from papain, although the UCH enzymes did not exhibit the same 
change in the KM value. The kinetic scheme for UCHL1 has been worked out by Case 
and Stein using the same Ub-AMC substrate [10]. Their study shows that the rate of 
acylation is rate-limiting for kcat, which means KM reduces to the dissociation constant 
(Kd) of the Michaelis complex. The fact that we are not seeing any significant change in 
KM suggests that Gln84 in UCHL1 does not contribute to the enzyme-ground state-
substrate complex. Therefore, in UCHL1, according to our studies, the active site 
glutamine does not make any appreciable contact with the substrate in the Michaelis 
complex; rather it helps to stabilize the transition state.  
The kinetic scheme for UCHL3 remains to be worked out. However, kcat values of 
UCHL3 catalyzed hydrolysis of ubiquitin ethylester and Ub-lysine are very similar to that 
obtained with Ub-AMC as the substrate, suggesting that deacylation might be the rate-
limiting step [13]. In such a case, KM is not the simple dissociation constant of the 
Michaelis complex. Nevertheless, the fact that KM changes only slightly upon glutamine 
to alanine mutation in UCHL3 is consistent with the inference that the glutamine does not 
appreciably contribute to Michaelis complex.  
As discussed before, we could not separately measure kcat and KM for 
UCHL5N240 Q82A; rather, the ratio was measured, which is about 16-fold less than the 
wild-type protein. It is possible that the ratio reflects a change mostly in kcat, like UCHL1 
and UCHL3, due to the structural similarity between the proteins. However, it cannot be 
ruled out that UCHL5N240 employs a different mechanism than UCHL1 and UCHL3. It 
is possible that there was a much larger change in kcat that was compensated by an 
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opposite change in KM. Alternatively, there was little or no change in kcat and the 
observed effect was due mostly to a change in KM. The latter possibility seems rather 
unreasonable since the glutamine is located in an almost identical position as in the other 
enzymes and therefore its effect on stabilizing the Michaelis-Menten complex is expected 
to be the same.  
Our results indicate the mutation of glutamine to alanine results in a significant 
decline in the catalytic rate, which supports the hypothesis that glutamine is functioning 
to stabilize the transition state intermediate(s). However, one expects that the change 
would be much greater than 30-fold as seen in our system if the mechanism were through 
the stabilization of the oxyanion, which has been proposed to involve hydrogen bonding 
between the NH2 group of the side chain of glutamine and the negatively charged oxygen 
ion, given that such hydrogen bonds are particularly strong. For example, mutation of the 
oxyanion-stabilizing residue Tyr16 to phenylalanine in ketosteroid isomerase results in a 
20,000-fold (6.3 kcal/mol) reduction in kcat [9]. One explanation for the discrepancy 
between the result of the mutation of the oxyanion-stabilizing side chain in ketosteroid 
isomerase compared to our system is that, in the latter, the side chain of glutamine is not 
solely responsible for stabilizing the oxyanion through hydrogen bonding; rather, it is 
playing a role in contributing to the overall electropositive character of the oxyanion hole. 
As shown in Figure 2.2, a number of αNH dipoles from surrounding backbone residues 
can still support a significant degree of oxyanion stabilization even in the absence of the 
glutamine side chain. Since main-chain atoms cannot be removed by traditional 
mutagenesis methods, the individual contribution of each atom cannot be determined, nor 
can we determine if the glutamine plays a more significant role than the individual 
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backbone atoms. The alternative possibility that the transition-state stabilization by the 
glutamine side chain is reflecting a somewhat weaker hydrogen bond owing to a longer 
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Table 2.1: Kinetic Parameters for UCH Enzymes showing decrease in kcat/KM from wild 
type to Ala mutants [1] 
 
Enzyme  KM (nM)  kcat (s-1)  




UCHL3  77.1 ± 8.2 18.60 ± 0.60  24140  
1.89  
UCHL3 Q89A  99.1 ± 13.5  1.03 ± 0.05  1040  
UCHL1  47.0 ± 6.0 0.0348 ± 1.25×10-3  74.1  2.19  
UCHL1 Q84A  56.1 ± 2.3 0.0011 ± 1.50×10-4  1.96  
UCHL5N240  21493.2  33.67  15.7  
1.68  UCHL5N240 









CHAPTER 3: CONSERVED HYDROPHOBIC MUTATION IN 
UCH ENZYMES HAS VARIED ROLE AS IT RELATES TO UBIQUITIN 
 
3.1 Abstract 
Ubiquitin carboxyl terminal hydrolase (UCH) enzymes release small peptide and 
protein leaving groups from the C-terminus of ubiquitin.  Although the interaction with 
ubiquitin is fairly well understood in these enzymes, recognition of the isopeptide moiety 
of the substrate at the active site has not been well characterized.  The crystal structure of 
TsUCH37 (T. spiralis) bound to the suicide substrate, UbVMe, reveals a conserved 
tryptophan residue that may play a role in stabilizing the isopeptide linkage in the active 
site.  To study the contribution of this tryptophan residue, the equivalent residue in 
human UCH37, W58, was mutated to alanine and phenylalanine.  The phenylalanine 
mutant retained most of its ubiquitin-AMC (Ub-AMC) hydrolysis activity as compared to 
the wild type enzyme, but the alanine mutant was substantially impaired.  The loss of 
activity with the alanine mutant is not due to any alteration in the three-dimensional fold 
of the enzyme.  Considering the distance of this tryptophan residue from G76 of ubiquitin 
(>5 Å), this observation suggests that W55 may be involved in binding to the AMC 
portion of the Ub-AMC substrate, which may indicate that it makes contact with the 
isopeptide moiety in ubiquitin-linked substrates.  This has been further investigated using 





Uch37 is a member of the ubiquitin carboxyl terminal hydrolase family. It is the 
only member of the family that has been found to be a resident of the proteasome.  Uch37 
binds to the 19s cap through an interaction at its C-terminus with the C-terminus of 
Rpn13 [2]. It is believed that this interaction activates Uch37 for cleavage of 
polyubiquitin chains by relieving the auto inhibition of the active site by helix 9, though 
this has yet to be experimentally proven [3, 4]. However this interaction provides 
additional ubiquitin binding sites that may contribute to the effectiveness of Uch37 
cleaving polyubiquitin chains. Uch37 has not shown to be activated unless it is bound to 
the 19S proteasome cap. At the proteasome Uch37 takes the role of chain as it process 
polyubiquitin chains at the distal end. Ubiquitin carboxyl terminal hydrolase (UCH) 
enzymes release small peptide and protein leaving groups from the C-terminus of 
ubiquitin . Although the interaction with ubiquitin is fairly well understood in these 
enzymes, recognition of the isopeptide moiety of the substrate at the active site has not 
been well characterized.  It was recently found that the tryptophan residue (Trp55) of 
TsUCH37 which is near the active site was in a particular confirmation that suggested it 
may interact with the isopeptide bond between ubiquitin and its linked substrates [5].  
The crystal structure of TsUCH37 (T. spiralis) bound to the suicide substrate, 
UbVMe, reveals a conserved tryptophan residue that may play a role in stabilizing the 
isopeptide linkage in the active site [5].  Considering the distance of this tryptophan 
residue from G76 of ubiquitin (>5 Å), this observation suggests that W55 may make 
contact with the isopeptide moiety in ubiquitin-linked substrates and have a role in 
ubiquitin binding or substrate release.  We found this interaction to be very intriguing, as 
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it made us wonder the significance of this individual residue. We hoped to identify if this 
tryptophan assists with monoubiquitin binding or does it have an effect on the ability of 
Uch37 to cleave ubiquitin bound substrates. It has been further suggested that the Trp55 
residue may provide important contacts with the isopeptide link, properly positioning for 
cleavage at the active site [5]. 
 
3.3  Materials and Methods 
Mutagenesis primers were ordered from Sigma Aldrich for Uch37(1-240) W58A 
and W58F. Using a Bioneer mutagenesis kit the mutagenesis was performed using 
standard parameters on the PCR thermocycler.  After PCR thermocylcling was compete 
the resulting mixtures were treated with the DPN1 enzyme to remove methylated parental 
DNA. The resulting mutagenesis reaction was transformed using Rosetta cells and plated 
overnight in a 37˚C incubator. The resulting plate produced a number of colonies. The 
mutant DNA was extracted using a mini-prep purification kit. The mutant DNA was 
submitted for sequencing to the Purdue Genomics Facility. The sequence results 
confirmed each mutation was successful (figure 3.2, 3.3, 3.4). The resulting DNA was 
transformed into Rosetta Component Cells.  
 
3.3.1 Mutagenesis, Protein Expression and Purification 
A 75 mL starter culture of Lennox broth (LB) inoculated with 100 ߤ݃/݉ܮ Ampicillin 
and Escherichia coli cells containing the desired protein construct. This culture was 
incubated at 37°C with vigorus shaking overnight.  The next day 6 x 1L of LB media was 
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inoculated with 100 ߤ݃/݉ܮ Ampicilin and 8 mls of the starter culture. The 6L cultures 
were grown to an optical density (O.D.λ=600nm) = 0.400 and then induced with 1.0 mM 
isopropyl B-D-1-thiogalactopyranoside (IPTG). The cultures were then allowed to grow 
overnight at 18°C. 
 Cells were harvested by centrifugation at 7000 x g for 10 minutes and 
resuspended in 60 mL of 1 X PBS buffer (phosphate-buffered saline plus 400 mM KCl). 
The cells were then lysed by French press at 1,000 psi after incubating for 30 minutes 
with approximately 600 mg of Lysozyme. The pressed cells were then centrifuged at 
1200 rpm (30,000 x g) to pellet the cell debris. The supernatant collected was then loaded 
on to a GSTPrep FF 16/10 glutathione sepharose affinity column, equilibrated with the 1 
X PBS solution, at a flow rate of 1ml/min. The column was then washed with the 60 ml 
of 1 X PBS buffer plus 400 mM KCl to remove non-specific binding elements. The 
desired protein was eluted with approximately 30 ml of elution buffer (250 mM 
Tris•HCL, 500 mM KCl, 10 mM reduced glutathione, pH 8.0).  About 500 units of 
PreScission Protease, a 47 kDa protein that recognizes and cleaves GST region of the 
protein between a Gln and Gly residues, was added to the eluted solution (citation needed 
GE website). This results in free GST (26 kDa) and free protein containing plus GPLGS 
peptide on the N-terminal.  The solution was dialyzed overnight at 4°C in a 1 X PBS 
buffer plus 400 mM KCl, to allow for sufficient cleavage of the GST tag. The solution 
was then loaded on to the GSTPrep FF 16/10 glutathione sepharose affinity column 
allowing the GST free protein to pass through the column while the cleaved GST stays 
bound in a process called GST subtraction. Fractions were taken from each step of the 
purification process and run on an SDS PAGE Gel for successful verification of the 
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isolated protein of interest.  The protein was then concentrated by centrifugation to 4 ml, 
filtered through a .25 micron syringe filter and loaded onto an S75 gel filtration column 
on an Akta protein purification system (GE Healthcare Life) with a running buffer of 50 
mM Tris-HCL 50 mM NaCl and 1 mM DTT (pH 7.4). The protein was collected in 2 ml 
fractions. An SDS PAGE Gel was run on the collected fractions to quantify were the 
protein eluted. The fractions containing the most concentrated eluted protein was then 
pooled and concentrated to around 2 ml. A small sample of protein taken for 
concentration measurement and the rest was aliquoted into 100 ml epindorf tubes, flash 
frozen in liquid nitrogen, and stored in -80˚C Ultra Freezer. 
 
3.3.2 Kinetic Analysis of Oxyanion Mutants 
Each of the hUCH37 (hUch37N240 WT, hUch37N240 W58A and hUch37N240 
W58F) and UCHL3 (UCHL3 and UCHL3 I58A) enzymes were diluted in assay reaction 
buffer (50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% BSA, 5 mM DTT) so the final 
concentration in the reaction is the following: Uch37N240 WT  (1 nM), Uch37N240 
W58A (1 nM), Uch37(N240)W58F (1 Nm), UCHL3 (50 pM), UCHL3 I58A (50 pM).  
Enzymes were added to a 96-well plate and incubated at 30°C for 5 min prior to addition 
of Ub-AMC diluted in assay reaction buffer to initiate the reaction. Rates of Ub-AMC 






3.3.3 Circular Dichroism 
Each of the hUCH37 (hUch37N240 WT, hUch37N240 W58A and hUch37N240 
W58F) were buffer exchanged into 1 X PBS buffer pH 7.4, to remove all traces of Tris 
HCL which absorbs strongly at 210 nm. Each protein was diluted to the final following 
concentrations: Uch37N240 WT (5 nM), Uch37N240 W58A (5 nM), Uch37N240 W58F 
(5 nM). CD spectra were obtained using a wavelength scan on a JASCO J-810 
spectrophotometer. Scans were conducted in the region of 260 to 190 nm.  Scans were 
corrected for blank and raw data converted to molar ellipticity. 
 
3.3.4 Isothermal Titration Calorimetry 
All solutions were dialyzed against 50 mM Tris-HCl 1mM TCEP.  In the titration 
of hUCH37N240 (WT) and ubiquitin, ubiquitin was diluted in buffer to 10 mM in 
syringe. hUCH37N240 (WT) was at a diluted to a concentration of 200 uM in cell.  In the 
titration of UCH37-RPN13N268 complex and Ubiquitin, the complex was diluted to a 
concentration of 100 uM in cell. Ubiquitin was diluted in buffer to 2 mM in syringe.  In 
the titration of hUCHL3 (WT) and ubiquitin and hUCHL3 I58A, ubiquitin was diluted in 
buffer to 500 μM in syringe. Both hUCHL3 (WT) and hUCHL3 I58A were diluted to a 
concentration of 59 μM for each titration. All ITC experiments were carried out by 
titrating free ubiquitin in syringe into the cell containing the respective UCH enzyme. 
Data was analyzed and fitted to a one-site binding model corresponding to a single site 
binding free ubiquitin to the perspective UCH enzyme being tested. Binding isotherm 




3.4  Results 
 
3.4.1 hUCH37N240 W58A and hUCH37N240 W58F 
The tryptophan (55) residue of TsUCH37 was observed to make contact with the 
OMe group, in the structurally characterized, TsUCH37cat-UBVME  which suggest an 
important contact with the hydrocarbon area of the isopeptide bond of an actual ubiquitin 
attached substrate [1]. We mutated this tryptophan (58) residue, conserved in all UCH37 
homologs, in hUCH37 to alanine and phenylalanine to test whether this contact is 
important for substrate binding or ubiquitin interaction with UCH37. The result was that 
the UCH37 enzyme showed no difference in Ub-AMC release between the hUCH37(1-
240) (wild-type)  and the W58F mutant. This comes as no surprise because the 
phenylalanine (F) mutation was a hydrophobic and structurally conservative mutation 
from the tryptophan (W) of that position and no change was expected. However, the non-
conservative mutation of W58A, gave a significant decrease in UCH37 ability to 
hydrolyze the Ub-AMC in comparison to the truncated wild-type and W58F mutation as 
revealed in figure 3.5. We attempted to quantify this change using Isothermal 
Calorimetry measurements of the hUCH37N240 (WT) and hUCH37N240 W58A.  ITC 
of the hUCH37N240 showed a very weak interaction with ubiquitin because it was 
outside of the KD of the ITC (KD < 1 mM) and is estimated to be near 10.5 mM. ITC of 
the mutant hUCH37N240 W58A   was not performed because the due to the WT protein 
not showing measurable binding to ubiquitin. We decided instead to measure the KD of 
UCH37-RPN13N268 complex. This is because previous literature indicates that UCH37 
has an increased affinity to ubiquitin when in complex with Rpn13, a resident of the 
39 
 
proteasome [5]. The ITC measurement of the complex also proved to be just outside of 
the range of the instrument and is estimated to be a KD: 1.6 ± 0.7 mM. So ITC proved to 
be not a conclusive way to determine whether the tryptophan mutation affects ubiquitin 
binding to hUCH37. 
 
3.4.2 UCHL3I28A 
The tryptophan of the hUCH37 is conserved in and other homologs [5].     
However sequence alignment of the UCH family as seen in figure 3.1 shows an 
isoleucine present in a similar position in UCHL3. We decided to test whether mutation 
to alanine would have the same effect as witnessed in hUCH37. Also UCHL3 provides 
an excellent model substrate because of its high affinity to ubiquitin. However, we 
observed that this mutation had almost no effect on UCHL3 ability to catalyze Ub-AMC 
as seen in figure 3.11. Similarly, analysis of the ITC data (figure 3.12) indicates that 
UCHL3 wild type protein and UCHL3I28A bind ubiquitin with dissociation constants 
(KD) of 669 ± 60 nM and 456 ± 62 nM, respectively.  We interpret from this that this 
isoleucine has no significant impact in ubiquitin binding or AMC release.   
 
3.5 Discussion 
 We sought to determine the contribution the role of the conserved tryptophan found near 
the active site of hUCH37N240. Through site-directed mutagenesis, the tryptophan residue, 
the equivalent residue in human UCH37, W58, was mutated to alanine and 
phenylalanine.  The phenylalanine mutant retained most of its ubiquitin-AMC (Ub-AMC) 
hydrolysis activity as compared to the wild type enzyme, but the alanine mutant was 
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substantially impaired.  The loss of activity with the alanine mutant is not due to any 
alteration in the three-dimensional fold of the enzyme.  Considering the distance of this 
tryptophan residue from G76 of ubiquitin (>5 Å), this observation suggests that W55 may 
be involved in binding to the AMC portion of the Ub-AMC substrate, which may indicate 
that it makes contact with the isopeptide moiety in ubiquitin-linked substrates. UCHL3, 
another structurally characterized member of the UCH family and excellent model DUB, 
was also studied by mutating the isoleucine, analogous to hUCH37 tryptophan, in order 
to assess the contribution to the isopeptide link near the active site. UB-AMC 
deubiquination assays show there is a significant loss of activity in the UCH37 W58A 
mutant enzymes compared to its wild-type counterparts. However, no effect was 
observed in the same assay with UCHL3 I58A and UCHL3 wild-type.  ITC analysis 
indicates that UCH37 does not tightly bind ubiquitin. We tested UCH37, UCH37 W58A, 
and UCH37-RPN13N268 complex but not able to observe appreciable binding to mono-
ubiquitin. We can reasonably determine that the tryptophan does have an appreciable impact on 
hUCH37  ability to cleave ubiquitnated substrates based on the Ub-AMC experimental results.  It 
would be reasonable to assume that this interaction is with the isopeptide bond and substrate and 
not with ubiquitin binding just based on distance (> 5 Å). What we also can determine is that this 
interaction is not seen in UCHL3 and based on structural similarity we can also rule out this 
effect in UCHL1.  However, at this time we are not able to experimentally rule out its effect on 
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CHAPTER 4: C—H•••O  HYDROGEN BONDS IN CYSTEINE PROTEASES 
 
4.1 Abstract 
Cysteine proteases have been extensively studied for their importance in a wide 
variety of biological processes such as apoptosis (Caspases), regulated proteolysis 
(ubiquitin hydrolases), and calcium signaling (Calpains). The mechanism of these 
proteolytic enzymes is relatively well known: it involves a catalytic diad of a cysteine-
histidine pair, or a triad with additional help of either an aspartic acid or asparagine. An 
analysis of structurally characterized cysteine proteases found in Merops Database 
reveals the presence of a close contact between the catalytic (His)CƐ and, most often, the 
O=Cδ of the putative oxyanion hole residue glutamine or a backbone carbonyl oxygen. 
This contact follows the requirements of a C-H---O hydrogen bond as previously reported 
for serine proteases (1).  We speculate that this C-H---O interaction may play a role in the 
catalysis by either altering the pKa of the general- base His and/or by keeping the 
oxyanion-stabilizing side chain in a productive orientation. Upon further analysis, we 
found that the oxyanion-stabilizing side chain, glutamine of ubiquitin carboxyl terminal 
hydrolases are engaged in a C—H•••O hydrogen-bonding interaction with the catalytic 
histidine, a feature that is common in most cysteine proteases, including papain, 
belonging to families with the QCH(N/D) type of active-site configuration.  It is possible 
that removal of the glutamine side chain might have abolished this interaction, which 
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typically accounts for 2 kcal/mol of stabilization, leading to an effect on catalysis 
observed here.    We investigated this further by making an additional mutation of the 
glutamine to glutamic acid and lysine in UCHL3. 
 
4.2 Introduction 
C—H•••O  hydrogen bonds have generally been identified by Taylor and 
Kenard[2] where a carbon is directly adjacent to a neutral or positively charged nitrogen, 
having an electron withdrawing effect. The result is that the carbon is more acidic and 
willing to donate its proton to a ready proton acceptor as long as the stereochemistry of 
the protein allows for it. It has been estimated that energy of this bond is 2.5 to 3.5 
kcal/mol in vaccuo [3]. In recent years several studies have identified  C—H•••O  
hydrogen bonds as having an important role in the stabilization of transmembrane 
helices[4], β sheets[5] and Schellman motifs[6]. However the role of this weak hydrogen 
bond in the activation of proteins is still not fully understood. 
C—H•••O  hydrogen bonds have also been identified in the active sites of serine 
protease.[7]  Derewenda et al. surmise that the significance of the C—H•••O  hydrogen 
bond is to provide an even charge distribution in the imidazole ring of histidine leading to 
the deprotonation of the NƐ2 during the cleavage step of acylation and deacylation of the 
enzyme[7]. Also that the bonds role is not necessary for stabilization of the imidazole 
ring because of the observed preferred trans conformation[7]. However, it has not been 
determined if these bond are present in the active sites of cysteine protease. Using 
generally accepted distance and angle measurements for C—H•••O  hydrogen bonds in 
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macromolecules we have determined the presence of C—H•••O  hydrogen bond in the 
active sites of cysteine proteases. 
 
4.3 Materials and Methods 
Using the Merops[1] a dataset of 94 non-homologous structurally characterized 
cysteine protease were selected. Each of their coordinate files were downloaded from the  
Protein Data bank[8]. A cutoff was for resolution at 3.0 Å and sequence homology of < 
80 %.  Hydrogen’s were added to the protein database coordinate files using the reduce 
program of Molprobity[9].   The stereo chemistry of the C—H•••O  bond was analyzed 
using the 4 different parameters and seen in Figure 1: C-O bond distance (D); O-H bond 
distance (DH); C—H•••O  angle (ζ); and H—O=C angle (ξ).  Geometric parameters used 
in previous C—H•••O  studies can be found in Table 1. The parameters as applied to this 
study limited the C-O bond distance (D) < 4.0Å, O-H bond distance (DH) <2.8Å, C—
H•••O  angle (ζ) > 120 (°)and the H—O=C angle (ξ) was measured but no specific cutoff 
was set. The calculation of the bond distances and angles were calculated using 
Pymol[10] and recorded into a table 4.4 
 
4.4 Results  
 
4.4.1   C—H•••O  Hydrogen Bond In Most Cysteine Protease Active Sites 
 
An analysis of the data reveals the presence of the C—H•••O  hydrogen bond in 
the active sites of cysteine proteases.  We identified 94 structurally characterized cysteine 
protease using the Merops[1]. Out of the 94 just 45 (48%) examples were identified as 
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having a distance C—H•••O  (D) of < 4.0 Å and an H—O (DH) distance of < 2.8 Å with 
an average of 3.52Å and 2.50Å respectively.  Figure 3A and 3B show the relative 
distribution of measured distances in the structures.  It reveals that a majority of the C—
H•••O  distances are between 3.5Å and 4.0Å. Also the H—O distances vary greatly but 
between 2.0Å to 2.8Å.   
The CƐ-H--O (ζ) angles were also well within the defined criteria of >1200 with an 
average of 1560, while the average H—O=C (ξ) angle was 1270. The distribution of angle 
measurements seen in Figure 3B and 3C are very spread out for the CƐ-H--O (ζ) angle 
and relatively tight for the H—O=C (ξ) angle.   These values are consistent with 
previously identified C—H•••O hydrogen bonds as reported in previous C—H•••O 
analysis in literature.   
The CƐ-H--O  hydrogen bond may have its importance in contributing to the 
effect on the charge distribution of the catalytic imidazole as suggested by Derewenda et 
al[7]. However we also noticed that glutamine was observed to be the most frequent 
proton acceptor in the analysis, involved in 32  (34%) of the total 94 proteins studied and 
is most noted to be the member of the putative oxyanion hole of cysteine protease. 
Previous studies have shown the importance of the oxyanion hole for the stabilization of 
the tetrahedral intermediate in the cysteine reaction mechanism and how mutation at this 
residue contributes to the reduction in enzyme activity[11]. From its prevalence as the 
proton acceptor in the importance of the C-H--O interaction may be to position the 
glutamine for immediate stabilization of the tetrahedral intermediate. Figure 4 shows the 
presence of the C—H•••O hydrogen bond in UCHL3 (PDB entry 1UCH), a notably very 
efficient cysteine protease. The glutamine is held in short contact with the catalytic 
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histidine. The CH is approximately 2.0 Å away from the oxygen of the side-chain 
carbonyl group. Interestingly, this distance is less than the sum of their van der Walls 
radii. This distance, along with C—H•••O and H•••O=C angles of 171° and 122°, 
respectively,  which meets the geometric criteria used for a C—H•••O hydrogen bond and 
therefore qualifies as a significant interaction [3, 4, 12-14]. Inspection of the active sites 
of UCHL1 (PDB ID: 3IFW) (bound with ubiquitin vinylmethylester) and UCHL5N240 
(PDB ID: 3RIS) also reveals the presence of the same interaction (Table 2), suggesting 
that the C—H•••O hydrogen bond involving the active site histidine and glutamine is a 
common feature of the UCH enzymes discussed herein [6, 12, 15]. 
 
4.4.2 UCHL3 Lysine and Glutamine Mutants Activity not as Expected 
In order to better understand the role of the glutamine side chain in the catalytic 
reaction, additional mutations converting the glutamine to either a glutamate or a lysine 
were carried out (Figure 6). Since results for the glutamine to alanine mutation were 
consistent across the three UCH enzymes tested, we limited the experiments to just 
UCHL3, which displayed the best geometry for the C—H•••O hydrogen bond among the 
UCH enzymes. Mutation of the glutamine to glutamate would allow for a stronger C—
H•••O bond but would eliminate its contribution to oxyanion stabilization. Furthermore, 
it would introduce a negative charge that is expected to destabilize the oxyanion species. 
Mutation to lysine, on the other hand, would take away the possibility of the C—H•••O 
bond while allowing for stronger oxyanion stabilization, assuming that the side-chain 
NH3+ group of the lysine would occupy a position similar to the NH2 group of the 
glutamine’s side chain.  As seen in the previous alanine mutants, replacing the glutamine 
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residue with either a glutamate or lysine lowered kcat, while KM remains relatively 
unchanged (Table 3). Surprisingly, the Q89E mutation resulted in only a 5-fold reduction 
in kcat compared to the wild-type enzyme, an effect that is significantly lower than what 
would be expected from the combined effect of both eliminating hydrogen-bonding and 
introducing charge-charge repulsion between the glutamate side chain and the oxyanion. 
In the case of Q89K, despite our expectation that the mutation would lead to better 
oxyanion stabilization, we see a 15-fold loss in kcat, which is roughly the value we see in 
the UCHL3 Q89A mutant (compare Table 3.1 with Table 2.1).  
In the analysis of 94 structurally characterized cysteine proteases we have seen 
evidence of the C—H•••O  hydrogen bond in about half of the cysteine protease that we 
have analyzed. 45 of the 94 exhibited C—H•••O  hydrogen bond from the active site 
Histidine (48%)[16].  32 cases were between the Histidine active site residue and the 
Glutamine oxyanion residue (34%).  We speculate that this interaction gives a greater 
importance for the role of the oxyanion hole residue in cysteine proteases by either 
altering the pKa of the general- base His and/or by keeping the oxyanion-stabilizing side 
chain in a productive orientation.  An alternative explanation of the difference in 
magnitude of Ub-AMC hydrolysis seen between the glutamine to alanine mutants 
compared to the wild-type enzymes can be made by invoking the loss of the C—H•••O 
contact in the mutant. Inspection of active sites of the UCH enzymes reveal that the 
glutamine is in short contact with the catalytic histidine, which satisfies the geometric 
constraints for a C—H•••O hydrogen bond. Intrigued by this, we looked at a larger 
dataset of QCH(N/D) type of cysteine proteases in the Merops database, which revealed 
most cysteine proteases, including papain, possess a conserved glutamine that is within 
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C—H•••O bonding distance of the catalytic histidine. It should be noted that in papain, 
the glutamine (Gln19) is also known to be involved in an N—H•••O hydrogen bond with 
the NH group of the side chain of Trp177 [17], a catalytically important side chain. This 
is an example of a carbonyl group simultaneously engaged in hydrogen bonding with a 
CH and an NH donor, a situation commonly observed among protein -sheets, in which 
the backbone carbonyl groups of one strand are engaged in C—H•••O and N—H•••O 
hydrogen bonds with an adjacent strand’s CH and backbone NH groups, respectively 
[18]. However this ‘bifurcated’ situation does not exist in UCH enzymes, as there is no 
other hydrogen bond donor with accepted distance other than the imidazole group of the 
catalytic histidine. The observation of the C—H•••O contact presented here extends the 
parallels between serine and cysteine proteases. Dewerenda et al. first observed a C—
H•••O contact involving the catalytic histidine and a backbone carbonyl as the hydrogen 
bond donor in the active site of serine proteases [12]. The possibility that such an 
interaction plays a role in the catalytic mechanism of cysteine proteases, as has been 
suggested for their serine counterparts, cannot be ruled out. Interestingly, the change in 
free energy of transition-state stabilization (close to 2 kcal/mol) upon mutation in our 
system, as well as in the case of papain, happens to be very much within the range of the 
strength of a C—H•••O hydrogen bond [3], [19]. 
The C—H•••O hydrogen bond can be thought of as an additional force that 
stabilizes the imidazole side chain in a productive orientation such that it acts both as a 
general base and a proton donor during catalysis. Additionally, the C—H•••O hydrogen 
bonding would serve to enhance the histidine’s ability to specifically act as a general base 
by transferring some electron density from the glutamine carbonyl to the imidazole ring 
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of histidine. A stronger general base would mean a better ability to extract proton from 
water to activate it for nucleophilic attack, facilitating the formation of the tetrahedral 
transition state during deacylation (Scheme 2.1). Although different cysteine proteases 
would employ different mechanisms for hydrolysis, a better general-base histidine will in 
general contribute to efficient catalysis. However, the exact mechanism of how the 
active-site C—H•••O interaction may play a role in transition-state stabilization needs to 
be further investigated by computational work. 
We conducted additional studies on UCHL3 to dissect the role of the glutamine 
side chain in the deubiquitination reaction. If the sole purpose of glutamine were to 
stabilize the oxyanion, removal of the hydrogen-bonding (N-H•••O) donor plus the 
placement of a negative charge would substantially destabilize the transition state, 
leading to an effect on kcat that would be greater than the alanine mutant. Interestingly, 
the glutamine to glutamate mutant (with only a 5-fold decrease in kcat) proved to be a 
better catalyst than the alanine mutant, which is inconsistent with the idea that the 
glutamine is acting as an oxyanion stabilizer. Instead, the data appears to support that the 
C—H•••O hydrogen bond contributes to catalysis.  It is likely that the carboxylate side 
chain of glutamate in the Q89E mutant makes a stronger C—H•••O interaction with the 
CH group of the catalytic histidine than the carboxamide group of glutamine resulting in 
a better catalyst than the wild-type protein, but this effect is compensated to some degree 
by the unfavorable electrostatics between the negatively charged side chain and the 
oxyanion. It should be noted that a previous study showed that Q19E mutation in papain 
resulted in an approximately 20-fold decrease in kcat, to a similar level as seen in the 
Q19A mutant, leading the authors of that study to propose that he negative charge was 
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tolerated in the active site [20]. It is tempting to propose that in papain, the 
accommodation of the unfavorable charge in the mutant might have also been due to the 
compensatory effect of the C—H•••O hydrogen bond. 
  We then mutated the glutamine to lysine, which produced an enzyme with 
activity comparable to the alanine mutant. This is also surprising because lysine side 
chain has two components, NH groups for hydrogen bonding with the oxygen of the 
oxyanion, and the charge for favorable electrostatic interaction, and we expected that the 
combination of the two, assuming that right geometry is maintained for the N-H•••O 
bond, would cause better stabilization of the oxyanion than in the wild-type protein. 
However, this mutant showed similar level of catalytic activity as the alanine mutant, 
indicating that placement of positive charge near the active site does not appreciably 
enhance the stability of the oxyanion species, presumably because the glutamine in the 
wild-type enzyme was not playing a role in oxyanion stabilization. Alternatively, the 
longer side chain of lysine may be oriented away from the oxyanion with little interaction 
between the two, and therefore, the lysine mutant may not be reporting if the glutamine 
were stabilizing the oxyanion.  On the other hand, since the Q89K mutant lacks the 
ability to form the C—H•••O hydrogen bond as the Q89A mutant, the reduction in kcat, to 
nearly the same extent as seen in Q89A, might reflect this deficiency.  
  
4.5 Discussion 
Earlier we have shown that the active-site glutamine in UCH enzymes contributes 
to rate enhancement, but the relatively modest value of transition-state stabilization is 
more indicative of a weaker interaction, such as the C—H•••O bond between the 
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glutamine and catalytic histidine, than the conventional N-H•••O type of hydrogen bond 
that was proposed to stabilize the oxyanion [21]. We now conclude as a result for the 
UCHL3 Q89K and Q89E that this active site glutamine gives all the characteristics of a 
C—H•••O hydrogen bond. The observation that the glutamate mutant of UCHL3 is more 
active than the alanine mutant suggests that the conserved glutamine is unlikely to 
contribute to oxyanion stabilization, rather may play a role in catalysis via the C—H•••O 
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D (Å) DH  (Å) CƐ-H--O (ζ) (°) 
 
H—O=C (ξ) (°) Reference 
<3.5 <2.7 >120 --  [4] 
-- <2.7 >90 ~120 [12] 
-- <2.8 >90 -- [22] 
4.0-30 <2.8 >110 120-140 [14] 
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Figure 4.2: Flowchart used to create database. Structurally characterized proteins 
identified in the Merops Database[1] which segregates proteins by catalytic type, family’s 
by sequence similarity, clan’s by evolutionary relationship. The pdbs were downloaded 














Table 4.2: C—H•••O  hydrogen bond parameters observed in 45 of 94 structurally 
characterized cysteine proteases.   Hydrogen bond donor and acceptor in bold. 
(a)Acceptor is backbone carbonyl oxygen of W280. (b) Acceptor is backbone carbonyl 






























N175,Q19 3.84 2.79 158.6 115.9 
1YAL 1.70 
C25, H159, 
N179 ,Q19 3.72 2.60 172.4 125.2 
1PPO 1.80 
C25, H159, 





2.97 1.90 164.0 128.4 
1KXR 2.07 
S115, Q109,  




a 2.50 128.2 139.6 
3IFW 2.4 
C90, H161, 
D176, Q84 3.71 2.79 141.6 159.1 
1UCH 1.80 
C95, H169, 






3.31 2.20 172.2 121.0 
1VJV 1.74 
C118, H447, 
N113, N465 3.10 2.10 147.3 102.4 
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3.27 2.20 156.8 126.2 
3K8U 1.90 
C17, H96, 
A112, Q11 3.59 2.70 136.2 153.6 
1CV8 1.75 
C24,  H120, 








3.96 2.88 167.2 74.7 
1Y08 1.93 
C94, H262, 
D284, D286 3.30 2.28 153.7 88.9 
2Z84 1.70 
C53, H177, 
D175, Y41 3.62 2.75 135.5 161.2 











































3C0R 2.31 C120,H222, D117 3.25 2.44 128.8 127.2 
3BIJ 2.50 C135, H84 3.14b 2.34 128.6 88.9 
1EUV 1.60 
C580,H514, 
D531,Q574 3.90 2.84 160.0 118.0 
2CKG 2.45 
C602,H533, 
D550,Q596 3.82 2.78 157.5 113.5 
3EAY 2.40 
C926,H794, 


















3.72 2.82 139.7 100.8 



























































3.79 2.69 174.6 138.3 
1EF7 2.67 
C31, H180, 
N200, Q22 3.88 2.81 163.9 144.6 
1CQD 2.10 
C27, H161, 
N181,  Q21 3.98 2.97 152.4 120.8 
2FO5 2.20 
C28, H167, 
















3.83 2.78 159.5 112.1 
1HUC 2.10 
C29,H199, 
















































N182, Q45 3.99 2.98 152.8 140.7 
1IWD 1.63 
C25, H159, 
N178, Q19 3.63 2.54 169.1 137.0 
2BDZ 2.10 
C25, H159, 
N175, Q19 3.57 2.49 168.8 130.2 
2PNS 1.90 
C25, H157, 
N173, Q19 2.88 2.01 132.6 101.0 
3F75 1.99 
C31, H167, 




3.40 2.38 154.7 137.7 
1CB5 2.59 
C73, H372, 
N396, Q67 3.71 2.65 162.1 114.6 
1GCB 2.20 
C73, H369, 
N392, Q67 3.75 2.68 165.9 126.7 
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Table 4.3: Kinetic Parameters for UCHL3 Glu and Lys mutants showing decrease in 
kcat/KM from wild type  
 
KM (nM)  kcat (s-1) kcat/KM ×104 (M-1 s-1) ΔΔG≠ (kcal/mol) 
UCHL3 Q89E  49.8 ± 11.0  3.65 ± 0.00 7329 0.72  
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Ubiquitin C-terminal hydrolases (UCHs) are cysteine proteases featuring a
classical Cys–His–Asp catalytic triad, and also a highly conserved Gln that
is thought to be a part of the oxyanion hole. However, the contribution of
this side chain to catalysis by UCHs is not known. Herein, we demonstrate
that the Gln side chain contributes to rate enhancement in UCHL1,
UCHL3, and UCHL5. Mutation of the Gln to Ala in these enzymes
impairs the catalytic efficiency, mainly because of a 16-fold to 30-fold
reduction in kcat, which is consistent with a loss of approximately
2 kcalÆmol)1 in transition state stabilization. However, the contribution to
transition state stabilization observed here is rather modest for the side
chain’s role in oxyanion stabilization. Interestingly, we discovered that the
carbonyl oxygen of this side chain is engaged in a C–HÆÆÆO hydrogen-bond-
ing contact with the CeH group of the catalytic His. Upon further analysis,
we found that this interaction is a common active site structural feature in
most cysteine proteases, including papain, belonging to families with the
QCH(N ⁄D) type of active site configuration. It is possible that removal of
the Gln side chain might have abolished the C–HÆÆÆO interaction, which
typically accounts for 2 kcalÆmol)1 of stabilization, leading to the effect on
catalysis observed here. Additional studies performed on UCHL3 by
mutating the Gln to Glu (strong C–HÆÆÆO acceptor but oxyanion destabili-
zer) and to Lys (strong oxyanion stabilizer but lacking C–HÆÆÆO hydrogen-
bonding capability) suggest that the C–HÆÆÆO hydrogen bond could contri-
bute to catalysis.
Introduction
Ubiquitin (Ub) C-terminal hydrolases (UCHs) belong
to a larger group of enzymes collectively called
deubiquitinases, which catalyze the hydrolysis of the
peptide or isopeptide bond through which Ub is
attached to other proteins or other Ub moieties in
polyubiquitin chains [1–5]. The UCH family members
are cysteine proteases featuring a classical Cys–His–
Asp catalytic triad [6–10]. The active site of these
enzymes also features a highly conserved Gln (Fig. 1),
which is believed to be a part of the so-called oxyanion
hole, an arrangement of spatially proximal peptide
dipoles aligned in a way that creates a positively
charged pocket facing the thiol group of the catalytic
Cys. It is also possible that, by virtue of being located
at the N-terminus of a helix, the electropositive charac-
ter of this pocket is enhanced by the helix macrodipole
effect [11]. In cysteine proteases, nucleophilic attack on
the carbonyl group of the scissile peptide bond pro-
ceeds through a tetrahedral transition state bearing a
negative charge on the oxygen atom of the carbonyl
group. This negative charge is stabilized by
electrostatic and hydrogen-bonding interactions with
Abbreviations
AMC, aminomethylcoumarin; PDB, Protein Data Bank; Ub, ubiquitin; Ubal, ubiquitin aldehyde; UCH, ubiquitin C-terminal hydrolase.
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the oxyanion hole, which are proposed to constitute
one of the factors leading to the lowering of activation
energy for the hydrolysis reaction [12].
The relative orientation of the carbonyl oxygen of
the scissile peptide group with respect to the oxyanion-
stabilizing groups, as in the tetrahedral transition state,
may be approximately visualized in the crystal struc-
ture of the yeast Ub hydrolase Yuh1 bound covalently
to the suicide substrate Ub aldehyde (Ubal) (Fig. 2)
[13]. Attack of the catalytic thiol on Ubal results in the
formation of the thiohemiacteal product, which mimics
the oxyanion-bearing tetrahedral transition state
(Fig. 2). As seen in Fig. 2, the hydroxyl oxygen of the
thiohemiacetal moiety is within a relatively short dis-
tance from the backbone NH groups of the catalytic
Cys90, Ala89 and Asn88 and the side chain NH2
group of Gln84, the putative oxyanion-stabilizing side
chain. It has been proposed that, in a general cysteine
protease, the negatively charged oxygen in the tetrahe-
dral transition state would occupy nearly the same
position as the thiohemiacteal hydroxyl oxygen seen in
the Yuh1–Ubal structure and would be coordinated
through electrostatic and hydrogen-bonding interac-
tions with the groups lining the oxyanion hole [13].
Previous studies in papain revealed that Gln19, the
oxyanion side chain in the protein, plays a role in the
catalytic mechanism of the enzyme contributing to rate
enhancement. Mutation of this side chain to Ala
reduces the catalytic efficiency by approximately
60-fold, mostly affecting kcat (20-fold lower), with a
smaller change in Km (three-fold higher) [12]. Ignoring
the relatively small change in Km, the 20-fold change
in kcat was attributed to a loss of the contribution of
the Gln side chain to oxyanion stabilization. The cata-
lytic Cys–His–Asp triad of structurally characterized
UCHs, such as UCHL1, UCHL3, and UCHL5, adopts
a similar geometric relationship as found in the Cys–
His–Asn triad of papain and the triads of other
papain-like cysteine proteases. Additionally, the active
site Gln in UCH enzymes is located in an analogous
position to Gln19 in the active site of papain. How-
ever, the role played by this side chain in catalysis by
UCHs has not been studied thus far. Considering the
importance of the UCH group of proteases in diseases
such as Parkinson’s disease and cancer, dissecting the
role of active site residues in catalysis by these enzymes
is an important endeavor, as it would advance our
understanding of the mechanism of these enzymes
[14–18]. In this study, we sought to determine the con-
tribution to rate enhancement by the putative oxyan-
ion-stabilizing side chain of the active site Gln by
mutational analysis and comparison of the kinetic
parameters with those of the wild-type proteins. This
was investigated in all structurally characterized
UCHs – UCHL1, UCHL3, and the catalytic domain
of UCHL5 (residues 1–240, hereafter referred to as
UCHL5N240) [6–10]. Breast cancer early-onset 1-asso-
ciated protein 1, the remaining human UCH family
member, was omitted from this study, as its crystal
structure has yet to be determined.
Results
Active site Gln fi Ala mutants of UCHs show
significantly less activity than the wild-type
enzymes
In order to determine whether the conserved Gln
found in the active site of UCHs (Fig. 1) contributes
to rate enhancement, hydrolysis assays with the fluoro-
genic substrate Ub-aminomethylcoumarin (AMC) were
Fig. 2. Ubal (gray) covalently bound to Yuh1 (green). Hydrogen
bonding distances are shown for Yuh1 residues stabilizing the thio-
hemiacetal hydroxyl oxygen on the aldehyde moiety. The helix of
Yuh1 that may contribute to the macrodipole is in magenta.
Fig. 1. Sequence alignment of the human UCHs and the yeast
homolog Yuh1. Residues corresponding to the catalytic triad are in
red, and the putative oxyanion residue is in blue.
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conducted, with identical conditions for each enzyme
and its Gln fi Ala mutant. These results showed that
the rate of hydrolysis leading to AMC release was sig-
nificantly reduced for the mutants as compared with
their wild-type counterparts (Fig. S1), suggesting a role
for this side chain in contributing to rate enhancement
in the catalytic mechanism of the enzymes. As Gln is
located in the solvent-accessible active site of the
enzymes, the mutation of this residue to Ala is not
expected to cause any significant perturbation in the
active site structure or gross changes in the three-
dimensional fold of the protein. In fact, the CD spec-
tra of the mutants produced patterns that were nearly
identical in shape and intensity to those of their corre-
sponding wild-type proteins (Fig. S2), confirming that
the mutation has no observable structural effect in
these proteins.
The reduction in catalytic activity observed upon
mutation could be attributable to two possible factors:
an increase in Km, or a reduction in kcat, the rate con-
stant of the rate-determining step in the hydrolysis
reaction. In order to determine which parameters are
affected by the mutation, we set out to analyze the
Michaelis–Menten kinetics of the mutants and the
wild-type enzymes. Additional activity assays were
conducted with varying substrate concentrations, and
plots of the initial velocities versus substrate concentra-
tion are shown in Fig. 3. All enzymes, with the excep-
tion of UCHL5N240 Q82A, were fitted to the
Michaelis–Menten equation (Fig. 3F). Nonlinear
regression analysis of the plots yielded the kinetic
parameters kcat and Km for each UCH variant, and
their values are provided in Table 1. The values of the
kinetic parameters obtained with wild-type enzymes
were consistent with previously reported values [19–
21]. For UCHL1 and UCHL3, the Gln fi Ala mutants
showed 30-fold and 18-fold decreases in kcat, respec-
tively, as compared with their corresponding wild-type
enzymes. However, Km values were relatively
unchanged by the mutation, which is consistent with
the hypothesis that the Gln is involved in the catalytic
mechanism of the enzyme.
In the case of UCHL5N240 Q82A, kcat and Km
could not be determined individually, because, even at
concentrations of Ub-AMC as high as 12 lm, the
Michaelis–Menten plot was still rising linearly with
substrate concentration, not reaching the plateau that
is diagnostic of saturation. Substrate concentrations
> 12 lm result in dimethylsulfoxide concentrations
higher than 5%, which can diminish the enzyme’s
activity. Instead, the kcat ⁄Km ratio was determined by
dividing the slope of this linear plot by the total
enzyme concentration, as it can be assumed that, in
this region of the Michaelis–Menten plot, [Ub-
AMC] > Km. Comparison of this value for the wild-
type and Q82A variant of UCHL5N240 showed a
16-fold reduction in catalytic efficiency, which was
comparable to the reductions seen with UCHL1 and
UCHL3, suggesting that Gln82 is probably performing
the same function as in the other UCH enzymes.
In order to determine the effect of these mutations
on the stabilization of the transition state, we sought
to estimate the change in free energy of activation
associated with the mutation. The calculation was car-
ried out with Eqn (1) and the kcat ⁄Km values men-
tioned above and reported in Table 1 [12]. The free
energy change for the three enzymes was approxi-
mately 2 kcalÆmol)1, which is consistent with the value
reported for the same mutation in papain [12].
DDG 6¼¼ RT ln ðkcat=KmÞmutantðkcat=KmÞwild-type
" #
ð1Þ
The active site Gln in UCHs is involved in a
C–HÆÆÆO hydrogen bond with CeH of the catalytic His
The loss in enzymatic activity seen in the Gln fi Ala
mutants prompted us to look closely at the inter-
actions of the active site Gln with nearby residues.
Figure 4 shows the active site neighbors of Gln in
UCHL3 [Protein Data Bank (PDB) entry 1UCH].
Interestingly, the Gln is in close proximity to the cata-
lytic His, with the CeH being 2.0 A˚ away from the
oxygen of the side chain carbonyl group, a distance
less than the sum of their van der Waals radii. This
distance, along with C–HÆÆÆO and HÆÆÆO=C angles of
171 and 122, respectively, meets the geometric crite-
ria used for a C–HÆÆÆO hydrogen bond, and this inter-
action therefore qualifies as a significant interaction
[22–26]. Inspection of the active sites of UCHL1 (PDB
ID: 3IFW) (bound with Ub vinylmethylester) and
UCHL5N240 (PDB ID: 3RIS) also reveals the pres-
ence of the same interaction (Table 2), suggesting that
the C–HÆÆÆO hydrogen bond involving the active site
His and Gln is a common feature of the UCHs dis-
cussed herein [22,27,28].
This observation led us to wonder whether such a
hydrogen bond also exists in papain and other papain-
like cysteine proteases. To this end, we created a data-
set of structurally characterized cysteine proteases
found in the MEROPS database that contain, in addi-
tion to the three members of the catalytic triad
CH(N ⁄D), the conserved Gln in their active site (see
Experimental procedures) [29]. The list of all proteins
in the dataset and relevant information about them is
Role of active site glutamine in UCH catalysis D. A. Boudreaux et al.
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presented in Table 2. The His–Gln (Ce–Od) distance
and angle distributions within the members of the
dataset are shown as a histogram in Fig. 5. Of 46
structures, 80% (37) satisfied the criteria for a C–HÆÆÆO
interaction. The remaining nine proteins met the
angular requirements for the C–HÆÆÆO bond, but did
not meet the distance requirements. However, it should
be noted that, in general, a hydrogen bond has a sig-
nificant electrostatic component, which will be func-




Fig. 3. Deubiquitination activity assay for determination of catalytic parameters. Data were fitted to the Michaelis–Menten equation to deter-
mine the kcat and Km parameters for each enzyme and the corresponding Gln fi Ala mutants. Wild-type UCHL1 (A) and UCHL1 Q84A (B)
are shown as squares, wild-type UCHL3 (C) and UCHL3 Q89A (D) are shown as diamonds, and wild-type UCHL5N240 (E) and UCHL5N240
Q82A (F) are shown as circles.
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weaker effect [24]. Among the 37 structures that met
the criteria, there were five instances in the dataset
where inactive forms of the protein did not meet C–
HÆÆÆO specifications; however the bond criteria were
satisfied once the protein was in an active conforma-
tion upon complexation with either an inhibitor or a
substrate mimic (Table 2). Table 2 shows that a major-
ity of the C–HÆÆÆO distances were between 3.1 and
4.5 A˚, with a mean value of 3.7 A˚. Additionally, the
HÆÆÆO distances varied between 2.1 and 3.3 A˚ with a
mean value of 2.6 A˚. The Ce–HÆÆÆO (f) angles were
also well within the defined criteria of > 120, with a
mean of 161, whereas the mean HÆÆÆO=C (n) angle
was 134.
In order to better understand the role of the Gln
side chain in the catalytic reaction, additional muta-
tions converting the Gln to either a Glu or a Lys were
carried out (Fig. 6). As the results for the Gln fi Ala
mutation were consistent across the three UCHs
tested, we limited the experiments to just UCHL3,
which displayed the best geometry for the C–HÆÆÆO
hydrogen bond among the UCHs. Mutation of the
Gln to Glu would allow for a stronger C–HÆÆÆO bond,
but would eliminate its contribution to oxyanion sta-
bilization. Furthermore, it would introduce a negative
charge that is expected to destabilize the oxyanion spe-
cies. Mutation to Lys, on the other hand, would take
away the possibility of the C–HÆÆÆO bond while allow-
ing for stronger oxyanion stabilization, on the assump-
tion that the side chain NH3
+ group of the Lys would
occupy a position similar to the NH2 group of the Gln
side chain. As seen in the previous Ala mutants,
replacing the Gln with either a Glu or a Lys lowered
kcat, whereas Km remained relatively unchanged
(Table 3). Surprisingly, the Q89E mutation resulted in
only a five-fold reduction in kcat as compared with the
wild-type enzyme, an effect that is significantly lower
than what would be expected from the combined effect
of both eliminating hydrogen bonding and introducing
charge–charge repulsion between the Glu side chain
and the oxyanion. In the case of the Q89K mutant,
despite our expectation that the mutation would lead
Table 1. Kinetic parameters for UCHs.
Enzyme Km (nM) kcat (s
–1)




UCHL3 77.1 ± 8.2 18.60 ± 0.60 24 140 1.89
UCHL3 Q89A 99.1 ± 13.5 1.03 ± 0.05 1040
UCHL1 47.0 ± 6.0 (0.0348 ± 1.25) · 10)3 74.1 2.19
UCHL1 Q84A 56.1 ± 2.3 (0.0011 ± 1.50) · 10)4 1.96
UCHL5N240 21 493.2 33.67 15.7 1.68
UCHL5N240 Q82A – – 0.966
Fig. 4. Ribbon diagram of UCHL3 with the catalytic residues and the C–HÆÆÆO bonding Gln shown as sticks. (A) The D-value. (B) The DH-value
along with the n and f angles.
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Table 2. C–HÆÆÆO hydrogen bond parameters observed in 46 structurally characterized cysteine proteases with QCH(N ⁄D)-type active site
configurations from the MEROPS database.
Clan Family PDB Protein Resolution
Active site
residues D (A˚) DH (A˚) f () n ()
CA C1 1PE6 Papain 2.1 Q19, C25, H159, N175 3.7 2.6 167.4 135.6
1YAL Chymopapain 1.7 Q19, C25, H159, N179 3.7 2.6 172.4 125.2
1PPO Caricain 1.8 Q19, C25, H159, N179 3.7 2.7 153.0 130.4
1GEC Glycyl endopeptidase
(Carica papaya)
2.1 Q19, C25, H159, N179 3.6 2.1 179.1 150.0
2ACT Actinidain 1.7 Q19, C25, H162, N182 3.5 2.5 162.0 124.0
1FH0a Cathepsin V 1.6 Q19, C25, H163, N187 4.2 3.2 162.7 137.9
1S4V Vignain 2.0 Q20, C26, H163, N183 3.8 2.7 174.6 138.3
1EF7b Cathepsin X 2.7 Q22, C31, H180, N200 3.9 2.8 163.9 144.6
1CQDa Zingipain 2.1 Q21, C27, H161, N181 4.0 3.0 152.4 120.8
1M6D Cathepsin F 1.7 Q19, C25, H159, N175 3.8 2.8 146.7 155.6
2FO5 Endopeptidase B
(barley-type)
2.2 Q22, C28, H167, N188 3.7 2.6 162.2 118.0
1CS8 Cathepsin L 1.8 Q19, C25, H163, N187 3.7 2.6 168.8 131.4
1GLO Cathepsin S 2.2 Q19, C25, H164, N184 3.3 2.3 161.4 119.7
7PCK Cathepsin K 3.2 Q19, C25, H162, N182 3.5 2.4 173.9 154.1
1NB5b,c Cathepsin H 2.4 Q19, C25, H159, N158 3.4 2.4 152.3 162.4
1YVB Falcipain-2 2.7 Q19, C25, H159, N175 3.8 2.8 159.5 112.1
1HUCc Cathepsin B 2.1 Q23, C29, H199, N219 3.6 2.5 153.3 122.5
3BPM Falcipain-3 2.5 Q45, C51, H183, N182 3.9 2.8 165.0 98.9
1K3Bc Dipeptidyl-peptidase I 2.2 Q228, C234, H381, N403 3.4 2.3 172.4 131.2
2P86a Rhodesain 1.2 Q19, C25, H162, N182 4.3 3.3 152.8 141.3
1XKG Peptidase 1 (mite) 1.6 Q108, C114, H250, N270 3.4 2.3 165.0 135.6
1F2Aa Cruzipain 1.6 Q19, C25, H159, N175 4.1 3.0 164.0 137.7
1IWD Ervatamin B 1.6 Q19, C25, H159, N178 3.6 2.5 169.1 137.0
1O0Ea Ervatamin C 1.9 Q19, C25, H157, N173 4.0 3.0 168.1 131.3
2BDZ Mexicain 2.1 Q19, C25, H159, N175 3.6 2.5 168.8 130.2
3BCNc Ervatamin A 2.8 Q19, C25, H157, N173 3.1 2.1 154.7 150.9
3F75 TgCPL peptidase
(Toxoplasma gondii)
2.0 Q25, C31, H167, N189 3.5 2.4 174.0 139.5
2B1M Papain-like protein
SPE31 (Pachyrhizus erosus)
2.0 Q20, G25, H168, N188 3.4 2.4 154.7 137.7
1CB5 Bleomycin hydrolase (animal) 2.6 Q67, C73, H372, N396 3.7 2.7 162.1 114.6
C2 1KXR Calpain-1 2.1 Q109, C115, H272, N296 3.2 2.3 141.7 119.0
1MDW Calpain-2 2.0 Q99, C105, H262, N286 3.0 1.9 164.0 128.4
C12 3IFWb Ubiquitinyl hydrolase L1 2.4 Q84, C90, H161, D176 3.7 2.8 141.6 159.2
1UCH Ubiquitinyl hydrolase L3 1.8 Q89, C95, H169, D184 3.1 2.0 171.6 122.1
1CMXc Ubiquitinyl hydrolase YUH1 2.3 Q84, C90, H166, D181 4.1 3.1 159.4 140.8
3IHR Ubiquitin C-terminal hydrolase L5 3.0 Q82, C88, H164, D179 3.6 2.8 133.6 160.1
C39 3K8U Bacteriocin-processing peptidase 1.9 Q11, C17, H96, D112 3.6 2.7 136.2 153.6
C47 1CV8 Staphopain A 1.8 Q18, C24, H120, N141 3.5 2.4 160.4 138.3
1X9Ya Staphopain B 2.5 Q237, C243, H340, N360 4.0 2.9 164.6 123.4
CE C83 2BU3c c-Glutamylcysteine
dipeptidyltranspeptidase
1.4 Q64, C70, H183, D201 3.5 2.4 179.0 150.6
C5 1AVPa Adenain 2.6 Q115, C122, H54, E71 4.5 3.5 156.5 100.5
C48 3EAY SENP7 peptidase 2.4 Q920, C926, H794, D873 3.6 2.6 151.5 137.4
1XT9 SENP8 peptidase 2.2 Q157, C163, H102, D119 3.3 2.2 176.7 136.4
1EUVb Ulp1 peptidase 1.6 Q574, C580, H514, D531 3.9 2.8 160.0 145.6
2CKG SENP1 peptidase 2.5 Q596, C602, H533, D550 3.8 2.8 157.5 118.0
1TH0a SENP2 peptidase 2.2 Q542, C549, H478, D495 3.9 2.9 154.4 122.3
AVG 3.7 2.6 161.1 133.7
a Does not meet our criteria for CHO hydrogen bond. b Satisfies our criteria upon complex formation. c MOLPROBITY strongly suggested flip-
ping of Gln or His.
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to better oxyanion stabilization, we saw a 15-fold
reduction in kcat, which is approximately the value that
we saw in the UCHL3 Q89A mutant (compare Table 1
with Table 3).
Discussion
The UCH subfamily of deubiquitinases are cysteine
proteases with a catalytic triad similar to that seen in
the papain family. In each member of this family, as in
papain, there is a conserved Gln located in the active
site of the enzymes that is believed to stabilize the
incipient negative charge on the carbonyl of the scissile
bond during the transition state of the hydrolysis reac-
tion (Scheme 1). Indeed, mutation of the Gln19 in
papain to Ala resulted in a 60-fold decrease in catalytic
efficiency, owing mainly to a diminished catalytic
rate (20-fold) and a small loss in substrate binding
(three-fold). These results support the claim that the
conserved Gln side chain contributes to the stabiliza-
tion of the oxyanion transition state. Given the simi-
larity in certain active site residues between papain and
members of the UCH family, we wondered whether
the Gln would perform a similar role in the UCH fam-
ily. The study presented herein sought to address the
role of the conserved Gln in rate enhancement in three
UCHs.
Through site-directed mutagenesis, the active site
Gln in three structurally characterized members of the
UCH family was replaced with Ala, in order to assess
the contribution of this side chain to rate enhance-
ment. Deubiquitination assays show there is a signifi-
cant loss of activity in mutant enzymes as compared
with their wild-type counterparts. Comparison of the
kinetic parameters shows a 16-fold to 30-fold reduction
( 2 kcalÆmol)1) in the catalytic efficiency for the Gln
mutants, which is attributable mainly to a decrease in












































































Fig. 5. (A) Distribution of distances (D) between the active site His Ce–HÆÆÆO contact of the side chain or backbone carbonyl. (B) Distribution
of distances (DH) HÆÆÆO–C. (C) Distribution of angles between Ce–HÆÆÆO (f). (D) Distribution of angles between the HÆÆÆO–C (n) contact of the
side chain or backbone carbonyl.
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(for the mutant UCHL5, kcat and Km could not be sep-
arately determined). These results are in agreement
with the aforementioned results for papain, although
the UCHs did not exhibit the same change in Km
value. The kinetic scheme for UCHL1 has been
worked out by Case and Stein, using the same Ub-
AMC substrate [20]. Their study showed that the rate
of acylation is rate-limiting for kcat, which means that
Km is reduced to the dissociation constant (Kd) of the
Michaelis complex. The fact that we do not see any
significant change in Km suggests that Gln84 in
UCHL1 does not contribute to the enzyme–ground
state–substrate complex. Therefore, in UCHL1,
according to our studies, the active site Gln does not
make any appreciable contact with the substrate in the
Michaelis complex; rather, it helps to stabilize the tran-
sition state.
The kinetic scheme for UCHL3 remains to be
worked out. However, kcat values of UCHL3-catalyzed
hydrolysis of Ub ethylester and Ub-lysine are very sim-
ilar to that obtained with Ub-AMC as the substrate,
suggesting that deacylation might be the rate-limiting
step [19]. In such a case, Km is not the simple dissocia-
tion constant of the Michaelis complex. Nevertheless,
the fact that Km changes only slightly upon Gln fi Ala
mutation in UCHL3 is consistent with the inference
that the Gln does not appreciably contribute to the
Michaelis complex.
As discussed before, we could not separately mea-
sure kcat and Km for UCHL5N240 Q82A; rather, the
ratio was measured, which is about 16-fold less than
that for the wild-type protein. It is possible that the
ratio reflects a change mostly in kcat, as for UCHL1
and UCHL3, because of the structural similarity
between the proteins. However, it cannot be ruled out
that UCHL5N240 employs a different mechanism
from UCHL1 and UCHL3. It is possible that there
was a much larger change in kcat that was compen-
sated for by an opposite change in Km. Alternatively,
there was little or no change in kcat and the observed
effect was attributable mostly to a change in Km. The
latter possibility seems rather unreasonable, as the Gln
is located in an almost identical position as in the
other enzymes, and its effect on stabilizing the Micha-
elis–Menten complex is therefore expected to be the
same.
Our results indicate that the mutation of Gln to Ala
results in a significant reduction in the catalytic rate,
supporting the hypothesis that Gln functions to stabi-
lize the transition state intermediate(s). However, one
would expect the change to be much > 30-fold, as
seen in our system, if the mechanism acted through the
stabilization of the oxyanion, which has been proposed
to involve hydrogen bonding between the NH2 group
of the side chain of Gln and the negatively charged
oxygen ion, given that such hydrogen bonds are
particularly strong. For example, mutation of the
oxyanion-stabilizing residue Tyr16 to Phe in ketoster-
oid isomerase results in a 20 000-fold (6.3 kcalÆmol)1)
reduction in kcat [30]. One explanation for the discrep-
ancy between the result of the mutation of the oxyan-
ion-stabilizing side chain in ketosteroid isomerase and
our system is that, in the latter, the side chain of Gln
is not solely responsible for stabilizing the oxyanion
Fig. 6. Activity assay for UCHL3 mutants fitted to the Michelis–
Menten equation for determination of Km and kcat. (A) UCHL3
Q89E is shown as open circles. (B) UCHL3 Q89K is shown as filled
triangles.
Table 3. Kinetic parameters for UCHL3 mutants.
Km (nM) kcat (s
)1)




UCHL3 Q89E 49.8 ± 11.0 3.65 ± 0.00 7329 0.72
UCHL3 Q89K 58.5 ± 2.9 1.20 ± 0.00 1931 1.51
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through hydrogen bonding; rather, it plays a role in
contributing to the overall electropositive character of
the oxyanion hole. As shown in Fig. 2, a number of
aNH dipoles from surrounding backbone residues can
still support a significant degree of oxyanion stabiliza-
tion even in the absence of the Gln side chain. As
main chain atoms cannot be removed by traditional
mutagenesis methods, the individual contribution of
each atom cannot be determined, and nor can we
determine whether the Gln plays a more significant
role than the individual backbone atoms. The alterna-
tive possibility, that the transition state stabilization by
the Gln side chain reflects a somewhat weaker hydro-
gen bond, owing to a longer distance between the
donor and the acceptor (Fig. 2), cannot be ruled out.
An alternative explanation for the difference in mag-
nitude of Ub-AMC hydrolysis seen between the
Gln fi Ala mutants and the wild-type enzymes
involves the loss of the C–HÆÆÆO contact in the mutant.
Inspection of active sites of the UCHs reveals that the
Gln is in close proximity to the catalytic His, which
satisfies the geometric constraints for a C–HÆÆÆO hydro-
gen bond. Intrigued by this, we looked at a larger
dataset of QCH(N ⁄D)-type cysteine proteases in the
MEROPS database, and this revealed that most cyste-
ine proteases, including papain, possess a conserved
Gln that is within C–HÆÆÆO bonding distance of the cat-
alytic His. It should be noted that, in papain, Gln19 is
also known to be involved in an N–HÆÆÆO hydrogen
bond with the NH group of the side chain of Trp177
[31], a catalytically important side chain. This is an
example of a carbonyl group being simultaneously
engaged in hydrogen bonding with a CH and an NH
donor, a situation that is commonly observed among
Scheme 1. Mechanism for the hydrolysis of ubiquitinated constructs by UCHs. Active site residues of the enzyme are in black, and the
ubiquitinated substrate is in gray. The oxyanion interaction is indicated with dashed lines.
Role of active site glutamine in UCH catalysis D. A. Boudreaux et al.
1114 FEBS Journal 279 (2012) 1106–1118 ª 2012 The Authors Journal compilation ª 2012 FEBS
89
protein b-sheets, in which the backbone carbonyl
groups of one strand are engaged in C–HÆÆÆO and
N–HÆÆÆO hydrogen bonds with an adjacent strand’s
CaH and backbone NH groups, respectively [32].
However this ‘bifurcated’ situation does not exist in
UCHs, as there is no other hydrogen bond donor with
an acceptable distance other than the imidazole group
of the catalytic His. The observation of the C–HÆÆÆO
contact presented here extends the parallels between
serine and cysteine proteases. Dewerenda et al. first
observed a C–HÆÆÆO contact involving the catalytic His
and a backbone carbonyl as the hydrogen bond donor
in the active site of serine proteases [22]. The possibil-
ity that such an interaction plays a role in the catalytic
mechanism of cysteine proteases, as has been suggested
for their serine counterparts, cannot be ruled out.
Interestingly, the change in free energy of transition
state stabilization (close to 2 kcalÆmol)1) upon muta-
tion in our system, as well as in the case of papain,
happens to be very much within the range of the
strength of a C–HÆÆÆO hydrogen bond [26].
The C–HÆÆÆO hydrogen bond can be thought of as
an additional force that stabilizes the imidazole side
chain in a productive orientation such that it acts both
as a general base and as a proton donor during cataly-
sis. Additionally, the C–HÆÆÆO hydrogen bonding
would serve to enhance the His residue’s ability to spe-
cifically act as a general base by transferring some
electron density from the Gln carbonyl to the imida-
zole ring of His. A stronger general base would mean
a better ability to extract a proton from water to acti-
vate it for nucleophilic attack, facilitating the forma-
tion of the tetrahedral transition state during
deacylation (Scheme 1). Although different cysteine
proteases would employ different mechanisms for
hydrolysis, a better general base His will, in general,
contribute to efficient catalysis. However, the exact
mechanism by which the active site C–HÆÆÆO interac-
tion may play a role in transition state stabilization
needs to be further investigated by computational
work.
We conducted additional studies on UCHL3 to dis-
sect the role of the Gln side chain in the deubiquitina-
tion reaction. If the sole purpose of Gln were to
stabilize the oxyanion, removal of the hydrogen-bond-
ing (N–HÆÆÆO) donor plus the placement of a negative
charge would substantially destabilize the transition
state, leading to an effect on kcat that would be greater
than that in the Ala mutant. Interestingly, the
Gln fi Glu mutant (with only a five-fold decrease in
kcat) proved to be a better catalyst than the Ala
mutant, which is inconsistent with the idea that the
Gln is acting as an oxyanion stabilizer. Instead, the
data appear to support the idea that the C–HÆÆÆO
hydrogen bond contributes to catalysis. It is likely that
the carboxylate side chain of Glu in the Q89E mutant
undergoes a stronger C–HÆÆÆO interaction with the CeH
group of the catalytic His than the carboxamide group
of Gln, resulting in a better catalyst than the wild-type
protein, but this effect is compensated for to some
degree by the unfavorable electrostatics between the
negatively charged side chain and the oxyanion. It
should be noted that a previous study showed
that Q19E mutation in papain resulted in an approxi-
mately 20-fold decrease in kcat, to a similar level as
seen in the Q19A mutant, leading the authors of that
study to propose that the negative charge was toler-
ated in the active site [33]. It is tempting to propose
that, in papain, the accommodation of the unfavorable
charge in the mutant might have also been attributable
to the compensatory effect of the C–HÆÆÆO hydrogen
bond.
We then mutated the Gln to Lys, which produced
an enzyme with activity comparable to that of the Ala
mutant. This is also surprising, because the Lys side
chain has two components, NH groups for hydrogen
bonding with the oxygen of the oxyanion, and the
charge for favorable electrostatic interaction, and we
expected that the combination of the two, assuming
that right geometry is maintained for the N–HÆÆÆO
bond, would cause better stabilization of the oxyanion
than in the wild-type protein. However, this mutant
showed a similar level of catalytic activity as the Ala
mutant, indicating that placement of a positive charge
near the active site does not appreciably enhance the
stability of the oxyanion species, presumably because
the Gln in the wild-type enzyme was not playing a
role in oxyanion stabilization. Alternatively, the longer
side chain of Lys may be oriented away from the oxy-
anion with little interaction between the two. On the
other hand, as the Q89K mutant lacks the ability to
form the C–HÆÆÆO hydrogen bond, the reduction in kcat
to nearly the same extent as seen in the Q89A mutant
might reflect this deficiency.
In conclusion, we have shown that the active site
Gln in UCHs contributes to rate enhancement, but the
relatively modest value of transition state stabilization
is more indicative of a weaker interaction, such as the
C–HÆÆÆO bond between the Gln and catalytic His, than
the conventional N–HÆÆÆO type of hydrogen bond that
was proposed to stabilize the oxyanion. The observa-
tion that the Glu mutant of UCHL3 is more active
than the Ala mutant suggests that the conserved Gln is
unlikely to contribute to oxyanion stabilization, and
rather may play a role in catalysis via the C–HÆÆÆO
hydrogen bond with the catalytic His.
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The Ub-AMC used for hydrolysis assays was purchased
from Boston Biochem (Boston, MA, USA). The glutathione
affinity column (GSTPrep FF 16 ⁄ 10), gel filtration column
(HiLoad 16 ⁄ 60 Superdex 75) and PreScission protease were
purchased from GE Biosciences (Piscataway, NJ, USA). All
fluorescence assays were performed on a TECAN Genios
microplate spectrofluorometer. Buffer and salt components
were purchased from either Sigma-Aldrich (St Louis, MO,
USA) or RPI Corp. (Mount Prospect, IL, USA).
Mutagenesis, expression and purification of
proteins
The genes for UCHL1, UHCL3 and UCHL5N240 were
cloned into the pGEX-6P-1 vector with standard protocols,
and subsequently used to mutate the active site Gln to Ala
through PCR reactions with the Quickchange II (Agilent,
Santa Clara, CA, USA) site-directed mutagenesis kit. All
plasmids were transformed into Rosetta2 Escherichia coli
cells and grown to a A600 nm of 0.6 in LB medium supple-
mented with 100 lgÆmL)1 ampicillin, and then induced with
0.5 mm isopropyl thio-b-d-thiogalactoside and grown over-
night at 18 C. Cells were harvested at 6000 g and resus-
pended in 1· NaCl ⁄Pi + 400 mm KCl (buffer A). Cells
were passed through a French press twice at 1200 p.s.i.,
and the lysate was cleared by centrifugation at 30 000 g for
1 h. The supernatant was loaded onto a glutathione affinity
column, washed with three column volumes of buffer A,
and eluted with 250 mm Tris, 500 mm KCl, and 10 mm
reduced l-glutathione (pH 8.0). The eluted sample was dia-
lyzed against 1· NaCl ⁄Pi, 400 mm KCl, and 1 mm dith-
iothreitol, to which Precission Protease was added to
remove the glutathione S-transferase tag, which was cap-
tured on a glutathione–agarose affinity column. The result-
ing glutathione S-transferase-cleaved protein solution was
passed through a Superdex S75 gel filtration column with
50 mm Tris ⁄HCl (pH 7.6), 150 mm NaCl, and 1 mm dith-
iothreitol. Fractions containing purified protein were
pooled, concentrated, and then flash-frozen in liquid nitro-
gen and stored at )80 C until use.
Kinetic assay to measure Km and kcat values
Each of the UCHs was diluted in assay reaction buffer
(50 mm Tris, pH 7.6, 0.5 mm EDTA, 0.1% BSA, 5 mm
dithiothreitol), so that the final concentrations in the reac-
tion were as follows: UCHL1, 2 nm; UCHL1 Q84A, 8 nm;
UCHL3, 5 pm; UCHL3 Q89A, 175 pm; UCHL5N240,
500 pm; UCHL5N240 Q82A, 3 nm; UCHL3 Q89E, 12 pm;
and UCHL3 Q89K, 50 pm. Enzyme was added to a 96-well
plate, and incubated at 30 C for 5 min prior to addition of
Ub-AMC diluted in assay reaction buffer to initiate the
reaction. Rates of Ub-AMC cleavage were monitored with
an excitation wavelength of 380 nm and an emission wave-
length of 465 nm at 30 C. Initial reaction rates were calcu-
lated and plotted against Ub-AMC concentrations in
sigmaplot, and fitted to the Michaelis–Menten equation to
determine Km and kcat values.
C–HÆÆÆO analysis
From the MEROPS database, a dataset of 46 nonhomolo-
gous structurally characterized cysteine proteases were
selected belonging to families with a QCH(N ⁄D) type of
active site configuration [29]. Structures with a resolution
lower than 3 A˚ were excluded from the dataset. Each of the
coordinate files was downloaded from the PDB, and hydro-
gens were added to the protein structures with the reduce
program under molprobity [34,35]. The stereochemistry of
the C–HÆÆÆO bond was analyzed with the four different cri-
teria for parameters shown in Fig. 7: C–O bond distance
(D); HÆÆÆO bond distance (DH); C–HÆÆÆO angle (f); and
HÆÆÆO=C angle (n). The geometric parameters used in the
present and previous C–HÆÆÆO studies can be found in
Table 4. The bond distances and angles were calculated
with pymol (DeLano Scientific) and are shown in Table 2.
Fig. 7. Definition of geometric parameters. (A) Angular parameters.
(B) Distance parameters.
Table 4. Geometric parameters for C–HÆÆÆO hydrogen bonding
D (A˚) DH (A˚) f () n () Reference
£ 4.0 < 2.8 > 120 – Present
study
£ 3.5 < 2.7 > 120 – [23]
– < 2.7 > 90  120 [22]
– < 2.8 > 90 – [36]
4.0–3.0 < 2.8 > 110 120–140 [25]
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with such content; 
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licensing, for a fee (for example, a compilation produced for marketing purposes,
inclusion in a sales pack) 
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